Menu

Recent Interviews

Lewis Black, CEO, Almonty Industries

Lewis Black
CEO | Almonty Industries
100 King Street West, M5X 1C7 Toronto (CAN)

info@almonty.com

+1 (647) 438-9766

Interview with mine operator Almonty Industries: "Tungsten makes e-cars better"


Nick Luksha, President, Prospect Ridge Resources

Nick Luksha
President | Prospect Ridge Resources
1288 West Cordova Street Suite 2807, V6C 3R3 Vancouver (CAN)

info@prospectridgeresources.com

Interview Prospect Ridge Resources: These fillets taste good to the market


Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


03. November 2021 | 10:16 CET

Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?

  • Biotechnology
Photo credits: pixabay.com

The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.

time to read: 2 minutes by Stefan Feulner
ISIN: VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , BIONTECH SE SPON. ADRS 1 | US09075V1026


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Valneva - Waiting for the substance

The discussions about the various types of vaccines are endless. Besides the mRNA vaccines from BioNTech and Moderna, vector vaccines like AstraZeneca have been administered. Vaccination skeptics have criticized the mRNA vaccine in particular. Because of the accusation that it affects our genetic material, they have so far stayed away from protection against the coronavirus and are waiting for the first inactivated vaccine, which the Austrian-French Company Valneva wants to bring to approval.

Inactivated vaccines contain killed pathogens, i.e. pathogens that cannot reproduce or only their components. These are recognized by the body as foreign and stimulate the body's defense system to produce antibodies without the respective disease breaking out.

With a successfully completed capital increase and gross proceeds of approximately EUR 88.00 million, Valneva's vaccine projects are to be accelerated. The project pipeline is bulging. In addition to the COVID-19 vaccine VLA2001, additional money must be invested in the Chikungunya vaccine candidate VLA1553 and VLA15 for protection against Lyme disease. Studies to date show the potential of the inactivated vaccine. VLA2001 has achieved a higher level of antibodies with fewer side effects compared with the AstraZeneca vaccine in about 4,000 subjects over the age of 18, the Company said.

Cardiol Therapeutics - Blockbuster for the heart

An infection with the SARS-CoV-2 coronavirus can also attack the heart, and in some cases, possibly lead to myocarditis. Recently, it has also been discussed that inflammation of the heart muscle, and in some cases also of the pericardium, occurs in a few patients following the Covid-19 vaccination, especially with a so-called mRNA vaccine.

Cardiol Therapeutics, a Canadian biotechnology company listed on Nasdaq, focuses on producing pharmaceutical cannabidiol (CBD) products and the development of innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol's lead product, CardiolRX, a highly purified and concentrated oral cannabidiol formulation, is the focus of this effort and is currently being evaluated in a Phase II/III outcomes study.

The Company received positive news from Health Canada, which granted approval to continue work on the multicenter, double-blind, randomized, placebo-controlled Phase II study designed to evaluate the safety and tolerability of CardiolRx and its effects on myocardial regeneration in patients with acute myocarditis. The study is expected to enroll 100 patients in clinical centers in the United States, Canada and Europe.

Cardiovascular disease is the leading cause of death in the Western world, independent of SARS-CoV-2. Cardiol Therapeutics has successfully progressed through the phases to date and continues to have tremendous potential in a multi-billion dollar market.

BioNTech - In the wake of the partner

The share price of the Mainz-based biotech Company benefited from the third quarter figures of its partner Pfizer, which exploded due to the joint preparation Comirnaty. Sales increased by 130% to USD 24.1 billion. The main sales driver was the jointly developed compound.

If Comirnaty is excluded from the figures, revenue growth of only 7% to USD 11.1 billion remains. BioNTech itself will publish its 9-month figures on November 9.

The share price reaction shows investors' expectations with a 3% gain to EUR 282.20. Above the level of around EUR 285.00, there should be a renewed attack on the October high at EUR 304.00.


Infection figures are rising rapidly again, but the pace of vaccination is slowing. To achieve better protection against the virus, "booster" vaccinations for all are currently being discussed, which will, of course, give the already approved vaccines such as Comirnaty a further boost in sales. BioNTech is promising, while we should wait and see with Valneva. Cardiol Therapeutics also has enormous potential with its preparation against heart disease.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

25. November 2021 | 12:44 CET | by Fabian Lorenz

BioNTech, Valneva, Cardiol Therapeutics: Vaccination boosters also share boosters?

  • Biotechnology

The Corona pandemic has been with us all for a good 18 months now, and there is no end in sight. While the industrialized countries are boosting their vaccines, large parts of the world's population have still not been vaccinated for the first time. That means that shares of manufacturers of vaccines or drugs against COVID-19 will continue to be the focus of investors. Driven by the booster and mandatory vaccination discussions, BioNTech has left the correction behind, and the share is marching towards EUR 300. Drug developer Cardiol Therapeutics should now pick up again after the successful capital increase. In any event, analysts see price potential. Vaccine developer Valneva benefits from the EU order but has not yet recovered from Tuesday's "flash crash".

Read

24. November 2021 | 12:41 CET | by Nico Popp

BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer

  • Biotechnology

In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.

Read

19. November 2021 | 11:21 CET | by Armin Schulz

Valneva, Cardiol Therapeutics, Novavax - Is the Corona emergency brake coming?

  • Biotechnology

Today, the Robert Koch Institute reported 65,371 new infections, a new sad record. In Berlin, politicians are currently discussing how to proceed. Abolishing the free tests to increase the pressure on the unvaccinated has proven wrong in retrospect. The fact that booster vaccinations might be necessary was also not considered when the vaccination centers were closed. Now the first state is discussing the next lockdown. If the numbers continue to rise, the emergency brake will be pulled in Berlin sooner or later. In parts of Austria, it is already a reality. We take a look at three possible winners of a lockdown.

Read